<DOC>
	<DOCNO>NCT01661153</DOCNO>
	<brief_summary>This prospective observational study evaluate use clinical practice , efficacy safety Avastin ( bevacizumab ) combination paclitaxel first line patient HER2-negative metastatic breast cancer . Data collect eligible patient 2.5 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Combination With Paclitaxel First-Line Treatment Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally recurrent metastatic breast cancer No prior treatment metastatic locally recurrent disease Eastern Cooperative Oncology Group ( ECOG ) performance status 02 History clinical evidence brain metastasis Pregnancy Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) clinically significant ( i.e . active ) cardiovascular disease Major surgical procedure significant traumatic injury within 28 day prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>